Recognizing the widespread and devastating nature of the opioid crisis, AMCP formed the Addiction Treatment Advisory Group in 2015 based on the recommendation from the AMCP Partnership Forum, Breaking the Link between Pain Management and Opioid Use Disorder.
Extended-release opioid agonists and antagonists represent an alternative treatment strategy for opioid use disorder. However their value is low for the money, according to this summary of an ICER analysis published in JMCP.
The benefits of extended release opioid agonists and antagonists in the highly personalized space of opioid use disorder treatment are described in this JMCP article by the CMO of Drug & Alcohol Treatment Centers, Pathway Healthcare.
The benefits of extended release opioid agonists and antagonists in the highly personalized space of opioid use disorder treatment are described in this JMCP article by the CMO of Drug & Alcohol Treatment Centers, Pathway Healthcare.
Extended-release opioid agonists and antagonists represent an alternative treatment strategy for opioid use disorder. However their value is low for the money, according to this summary of an ICER analysis published in JMCP.